The 2023 MDMA-Assisted PTSD Trial: What Phase 3 Did Test
Key takeaways
- The trial compared two therapy-supported groups.
- Both arms improved on the primary symptom measure.
- Phase 3 does not mean regulatory approval.
A 2023 Nature Medicine phase 3 trial compared MDMA-assisted therapy with placebo plus the same therapy program in moderate-to-severe PTSD. It provides evidence about a combined intervention, not MDMA alone.
The comparison matters
Mitchell and colleagues enrolled 104 participants, assigning 53 to MDMA-assisted therapy and 51 to placebo with the therapy program. The relevant comparison includes support in both groups.
If a summary calls this simply a drug-versus-nothing trial, it misrepresents the design. The placebo-plus-therapy group is important to understanding the incremental difference.
The primary result
At the primary endpoint, the reported least-squares mean change in CAPS-5 PTSD severity was minus 23.7 points in the MDMA-assisted group and minus 14.8 in the comparator group. Functional impairment was also assessed.
Both groups improved. The difference is informative, but the improvement in the comparator arm should not disappear from a headline or a promotional account.
Interpretation and limits
Treatment assignment may be difficult to mask when experiences are noticeable. The therapy framework and study population also limit application to other settings or unsupervised use.
A complete benefit-risk reading requires the adverse-event reporting, eligibility criteria, follow-up, and full methods. An average symptom-score result cannot replace that broader assessment.
Phase 3 is not an approval
This article reports a September 2023 publication and makes no claim about a current regulatory decision. The phase label describes a research stage, not a guarantee of approval or commercial success.
Read our trial phase guide for the distinction between evidence generation and regulatory review. No stock recommendation follows from the result reported here.
Sources and further reading
Explore our research resources for help checking original sources.
Investment information: This article is educational, not a recommendation to buy or sell any security. Investments can lose value, including the entire amount invested. Research findings are not investment-return forecasts.
The accompanying picture is an illustrative editorial image, not a photograph of the cited study or its participants.
Written by
Psychedelic Stock Picks Editorial Team
Psychedelic Stock Picks Editorial Team covers the latest news and insights for Psychedelic Stock Picks.
PreviousPsychedelic Stocks: Start With Evidence, Not a Story
NextCash Runway and Dilution: Reading a Biotech Balance Sheet
